# Quarterly Update/Target price/Rating change





# **Dhanuka Agritech**

# Proxy play on uptick in agrochem demand

#### FY25 growth guidance robust

India | Agrochemicals

Dhanuka Agritech (DAGRI IN) reported mix Q4 - EBITDA was as estimated but PAT came in lower-than-anticipated, led by higher-thanexpected tax rate. Brand business volume grew 6.5% in Q4, lower than anticipated. The Technical business continued to operate at a low scale and is a loss-making venture for the time being. For FY25, DAGRI has guided for a robust 18% topline growth, driven by new product launches (at least three 9(3) molecules), scale-up of technical business and expectations of normal monsoons driven by La Nina.

#### Promotional expenses to hinder margin expansion in FY25

DAGRI plans to launch eight new products through FY25-26, which it intends to promote aggressively. Marketing and promotion expenses are expected to increase 100bps as a percentage of sales from 7% to 8%. Also, the benefit of low-cost inventory may ebb in FY25. Hence, despite an 18% topline growth guidance, DAGRI expects FY25 EBITDA margin at 18%, contracting 60bps YoY. But contrarily, we expect flat margin YoY as DAGRI should be able to contain costs, in our view. Higher promotional expenses with high likelihood of product launches should lay a strong foundation for consistent double-digit topline growth in the brand business in the next 3-4 years.

#### Valuation: Revise to Accumulate; TP raised to INR 1,417

DAGRI being a pure-play domestic branded company is a proxy play on any uptick in domestic agrochemical demand. Increased number of new product launches and investments in building up these brands, if supported by favorable climatic conditions, should lead to sustained 15% topline CAGR in the next 3-4 years.

High spends in promotional marketing may ensue temporary cost pressure in FY25. Hence, we downgrade FY25E EBITDA/PAT 8%/10% but upgrade FY26E EBITDA and PAT by 6% each assuming partial rationalization of these expenses. We revise DAGRI to Accumulate (from BUY), given the temporary cost pressure. But raise TP to INR 1,417 (from INR 1,287), on raised 18x (from 15x earlier) FY26E EPS of INR 79.

### Rating: Accumulate

Target Price: INR 1,417

Upside: 6%

CMP: INR 1,334 (as on 17 May 2024)

Key data	
Bloomberg /Reuters Code	DAGRI IN/DHNP.BO
Current / Dil. Shares O/S (mn)	47/47
Mkt Cap (INR bn/USD mn)	61/730
Daily Vol. (3M NSE Avg.)	61,729
Face Value (INR)	2

#### 1 USD = INR 83.3

Note: \*as on 17 May 2024; Source: Bloomberg

#### Price & Volume 1,500 1.5 1.0 1,000 0.5 500 0.0 Sep-23 Jan-24 May-24 Vol. in mn (RHS) -Dhanuka Agritech (LHS) Source: Bloombera

Shareholding (%)	Q1FY24	Q2FY24	Q3FY24	Q4FY24
Promoter	70.2	70.2	70.2	70.2
Institutional Investors	20.8	20.4	19.8	20.4
Other Investors	1.8	1.9	2.4	2.1
General Public	7.2	7.5	7.7	7.3

Source: BSE

Price performance (%)	3M	6M	12M
Nifty	1.9	13.9	23.6
Dhanuka Agritech	22.5	53.9	99.8
Rallis India	12.9	28.8	46.9
UPL	4.1	(9.0)	(24.6)

Source: Bloomberg

Consolidated financials (INR Mn)	Q4FY24	Q4FY23	YoY (%)	Q3FY24	QoQ (%)	FY24	FY23	YoY (%)
Cons Net Sales	3,683	3,712	(0.8)	4,032	(8.7)	17,585	17,002	3.4
Raw Materials	2,077	2,295	(9.5)	2,476	(16.1)	10,722	11,155	(3.9)
% of Net Sales	56.4	61.8	(543)bp	61.4	(503)bp	61.0	65.6	(464)bp
Employee Cost	372	285	30.3	400	(7.1)	1,554	1,263	23.0
Other Expenses	434	353	22.8	534	(18.8)	2,035	1,798	13.2
Total Expenditure	2,882	2,934	(1.8)	3,411	(15.5)	14,311	14,215	0.7
EBITDA	801	779	2.9	622	28.8	3,274	2,787	17.5
Margin (%)	21.7	21.0	77bp	15.4	633bp	18.6	16.4	223bp
Depreciation	132	51	158.2	129	2.3	406	176	130.4
EBIT	669	728	(8.0)	493	35.8	2,869	2,611	9.9
Interest	7	8	(8.3)	7	(4.7)	31	31	(0.7)
Other Income	153	147	3.7	73	109.9	350	448	(21.9)
PBT	815	867	(6.1)	558	46.0	3,188	3,027	5.3
Tax	225	214	4.9	105	115.0	797	692	15.1
Tax Rate (%)	27.6	24.7	287bp	18.7	885bp	25.0	22.9	212bp
RPAT	590	653	(9.6)	454	30.1	2,391	2,335	2.4
APAT	590	653	(9.6)	454	30.1	2,391	2,335	2.4
Adj EPS	12.7	14.0	(9.6)	9.7	30.1	51.3	50.1	2.4

YE	Revenue	YoY	EBITDA	EBITDA	Adj PAT	YoY	EPS	RoE	RoCE	P/E	EV/EBITDA
March	(INR mn)	(%)	(INR mn)	margin (%)	(INR mn)	(%)	(INR)	(%)	(%)	(x)	(x)
FY23	17,002	15.1	2,787	16.4	2,335	11.8	51.2	22.0	24.5	11.9	10.1
FY24	17,585	3.4	3,274	18.6	2,391	2.4	52.5	19.0	22.8	19.2	14.1
FY25E	20,723	17.8	3,840	18.5	2,778	16.2	60.9	19.8	23.7	21.7	15.8
FY26E	23,650	14.1	4,844	20.5	3,588	29.1	78.7	21.3	25.6	12.8	9.6




# Consolidated Financials (YE March)

Income Statement (INR mn)	FY23	FY24	FY25E	FY26E
Net Revenues	17,002	17,585	20,723	23,650
EBITDA	2,787	3,274	3,840	4,844
Less: - Depreciation & Amortization	176	406	509	532
EBIT	2,611	2,869	3,330	4,312
Less:- Interest Expenses	31	31	20	20
Add:- Non operating Income	448	350	402	503
PBT	3,027	3,188	3,712	4,794
Less :- Taxes	692	797	934	1,207
Adjusted PAT	2,335	2,391	2,778	3,588
Reported PAT	2,335	2,391	2,778	3,588
Balance Sheet (INR mn)	FY23	FY24	FY25E	FY26E
Share Capital	91	91	91	91
Reserves	10,522	12,468	13,967	16,727
Borrowings	38	5	-	
Deferred Tax (Net)	24	51	42	54
Trade Payable	1,752	1,495	1,987	2,268
Other Liabilities	1,626	1,682	1,985	2,286
Total Liabilities	14,053	15,791	18,072	21,426
Gross Block	2,519	4,522	4,643	5,242
Less:- Accumulated Depreciation	873	1,141	1,651	2,183
Net Block	1,646	3,381	2,992	3,059
CWIP	1,532	282	500	100
Other Non-Current Assets	1,913	1,870	1,959	1,998
Cash & bank balances	43	13	64	99
Inventory	3,451	4,179	4,429	5,054
Trade Receivable	3,390	3,468	3,974	4,536
Other Net Assets	2,078	2,598	4,154	6,579
Total Assets	14,053	15,791	18,072	21,426
Cash Flow Statement (INR mn)	FY23	FY24	FY25E	FY26E
Cash profit adjusted for non-cash items	2,806	3,347	3,831	4,857
Add/Less: Working Capital Changes	(711)	(1,208)	(70)	(777)
Taxes Paid	(733)	(794)	(897)	(1,158)
Operating Cash Flow	1,362	1,345	2,864	2,921
Less:- Capex	(1,242)	(893)	(498)	(200)
Free Cash Flow	121	451	2,367	2,721
Financing Cash Flow	(1,368)	(565)	(1,136)	(989)
Investing Cash Flow	26	(809)	(1,677)	(1,897)
Net change in Cash	20	(30)	51	35
Ratio Analysis	FY23	FY24	FY25E	FY26E
Income Statement Ratios(%)				
Revenue Growth	15.1	3.4	17.8	14.1
EBITDA Growth	5.8	17.5	17.3	26.2
PAT Growth	11.8	2.4	16.2	29.1
EBITDA Margin	16.4	18.6	18.5	20.5
Net Margin	13.7	13.6	13.4	15.2
Return & Liquidity Ratios (%)				
Net Debt/Equity (x)	(0.0)	(0.0)	(0.0)	(0.0)
ROE (%)	22.0	19.0	19.8	21.3
ROCE (%)	24.5	22.8	23.7	25.6
. ,				
rer snare data & valuation Ratios	51.2	52.5	60.9	78.7
Per Share data & Valuation Ratios Diluted EPS (Rs/Share)				15.2
Diluted EPS (Rs/Share)		13.6	1.3.4	13.7
Diluted EPS (Rs/Share) EPS Growth (%)	13.7	13.6 14.0	13.4 24.4	
Diluted EPS (Rs/Share) EPS Growth (%) DPS (Rs/Share)	13.7 2.0	14.0	24.4	21.3
Diluted EPS (Rs/Share) EPS Growth (%) DPS (Rs/Share) P/E Ratio (x)	13.7 2.0 11.9	14.0 19.2	24.4 21.7	21.3 12.8
Diluted EPS (Rs/Share) EPS Growth (%) DPS (Rs/Share) P/E Ratio (x) EV/EBITDA (x)	13.7 2.0 11.9 10.1	14.0 19.2 14.1	24.4 21.7 15.8	21.3 12.8 9.6
Diluted EPS (Rs/Share) EPS Growth (%) DPS (Rs/Share) P/E Ratio (x) EV/EBITDA (x) EV/Sales (x)	13.7 2.0 11.9 10.1 1.7	14.0 19.2 14.1 2.6	24.4 21.7 15.8 2.9	21.3 12.8 9.6 2.0
Diluted EPS (Rs/Share) EPS Growth (%) DPS (Rs/Share) P/E Ratio (x) EV/EBITDA (x)	13.7 2.0 11.9 10.1	14.0 19.2 14.1	24.4 21.7 15.8	21.3 12.8 9.6


Note: pricing as on 17 May 2024; Source: Company, Elara Securities Estimate

#### Revenue & margin trend




Source: Company, Elara Securities Estimate

#### Adjusted profit growth trend



Source: Company, Elara Securities Estimate

#### **Return ratios**



Source: Company, Elara Securities Estimate



#### Three products launched in Q1FY25

DAGRI has launched three new products in Q1FY25. *LaNevo* (a combination of Bifenthrin + Fluxametamide), licensed with Nissan Chemical Corporation, is a broad spectrum insecticide against sucking and chewing pest. The market size for the product is INR 10.5bn. *Purge* is a herbicide to control narrow leaf and broad leaf weed in soyabean and groundnut. The market size for purge is INR 7bn. *Mycore Super* is a biofertilizer, which facilitates better nutrient and water uptake. The market size for this brand is INR 5bn. DAGRI plans to launch one more product in Q1.

#### Technical business: Volume to scale up

The technical business clocked INR 75mn topline in FY24, which is expected to scale up to INR 500mn in FY25, driven by scale-up in production and new molecule commercialization. DAGRI has also set up a new chemical R&D laboratory with 30 chemists for chemical synthesis, which will accelerate product and process development capabilities. DAGRI plans to set up a new herbicide plant in FY25 but the investment amount is yet to be freezed.

Exhibit 1: Insecticide sales declined 5% in Q4

(INR mn)	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24
Insecticides	1,060	2,009	1,141	1,708	996	2,719	1,290	1,621
Fungicides	432	1,140	787	631	369	1,112	847	589
Herbicides	2,042	1,683	1,534	965	1,993	1,545	1,411	1,031
Others	393	597	472	408	332	803	484	442


Source: Company, Elara Securities Research

Exhibit 2: East India - 26% growth in sales

(INR mn)	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24
North	1,178	1,412	865	1,077	1,107	1,483	887	958
South	668	1,574	1,495	1,522	738	1,916	1,573	1,473
West	1,728	2,009	1,141	705	1,513	2,101	1,089	737
East	353	434	433	408	332	680	484	516

Source: Company, Elara Securities Research

Exhibit 3: Innovation turnover rate flat YoY



Source: Company, Elara Securities Research

**Exhibit 4: Change in estimates** 

	Old		New		% cha	nge
(INR mn)	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E
Net sales	20,949	23,718	20,723	23,650	(1.1)	(0.3)
EBITDA	4,193	4,568	3,840	4,844	(8.4)	6.0
EBITDA margin (%)	20.0	19.3	18.5	20.5	(149)bp	122bp
PAT	3,101	3,388	2,778	3,588	(10.4)	5.9
EPS (INR)	68.0	74.3	60.9	78.7	(10.4)	5.9
TP (INR)		1,287		1,417		10
Rating		Buy		Accumulate		

Source: Elara Securities Estimate



# **Coverage History**



	Date	Rating	Target Price	Closing Price
27	2-Feb-2022	Accumulate	INR 892	INR 777
28	7-Apr-2022	Buy	INR 1,045	INR 749
29	2-Aug-2022	Buy	INR 961	INR 695
30	1-Nov-2022	Buy	INR 993	INR 731
31	10-Feb-2023	Buy	INR 880	INR 683
32	2-Aug-2023	Accumulate	INR 880	INR 746
33	7-Nov-2023	Accumulate	INR 963	INR 874
34	2-Feb-2024	Reduce	INR 1,115	INR 1,130
35	6-Mar-2024	Buy	INR 1,287	INR 1,028
36	17-May-2024	Accumulate	INR 1,417	INR 1,334

<sup>\*</sup>AC = Analyst change

# **Guide to Research Rating**

BUY	Absolute Return >+20%
ACCUMULATE	Absolute Return +5% to +20%
REDUCE	Absolute Return -5% to +5%
SELL	Absolute Return < -5%



## Elara Securities (India) Private Limited

#### Disclosures & Confidentiality for non U.S. Investors

The Note is based on our estimates and is being provided to you (herein referred to as the "Recipient") only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient in understanding / evaluating the Proposal. Nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. Nevertheless, Elara Securities (India) Private Limited or any of its affiliates is committed to provide independent and transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Elara Securities (India) Private Limited or any of its affiliates have not independently verified all the information given in this Note and expressly disclaim all liability for any errors and/or omissions, representations or warranties, expressed or implied as contained in this Note. The user assumes the entire risk of any use made of this information. Elara Securities (India) Private Limited or any of its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for or solicit investment banking or other business from any company referred to in this Note. Each of these entities functions as a separate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This Note is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Elara Securities (India) Private Limited or any of its affiliates to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe, any such restrictions. Upon request, the Recipient will promptly return all material received from the company and/or the Advisors without retaining any copies thereof. The Information given in this document is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This Information is subject to change without any prior notice. Elara Securities (India) Private Limited or any of its affiliates reserves the right to make modifications and alterations to this statement as may be required from time to time. However, Elara Securities (India) Private Limited is under no obligation to update or keep the information current. Neither Elara Securities (India) Private Limited nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. This Note should not be deemed an indication of the state of affairs of the company nor shall it constitute an indication that there has been no change in the business or state of affairs of the company since the date of publication of this Note. The disclosures of interest statements incorporated in this document are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. Elara Securities (India) Private Limited generally prohibits its analysts, persons reporting to analysts and their family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited. It is important to note that any dispute with respect to this research report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Elara Securities (India) Private Limited was incorporated in July 2007 as a subsidiary of Elara Capital (India) Private Limited.

Elara Securities (India) Private Limited is a SEBI registered Stock Broker in the Capital Market and Futures & Options Segments of National Stock Exchange of India Limited [NSE], in the Capital Market Segment of BSE Limited [BSE] and a Depository Participant registered with Central Depository Services (India) Limited [CDSL].

Elara Securities (India) Private Limited's business, amongst other things, is to undertake all associated activities relating to its broking business.

The activities of Elara Securities (India) Private Limited were neither suspended nor has it defaulted with any stock exchange authority with whom it is registered in last five years. However, during the routine course of inspection and based on observations, the exchanges have issued advise letters or levied minor penalties on Elara Securities (India) Private Limited for minor operational deviations in certain cases. Elara Securities (India) Private Limited has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has the certificate of registration been cancelled by SEBI at any point of time.

Elara Securities (India) Private Limited offers research services primarily to institutional investors and their employees, directors, fund managers, advisors who are registered or proposed to be registered.

Details of Associates of Elara Securities (India) Private Limited are available on group company website www.elaracapital.com

Elara Securities (India) Private Limited is maintaining arms-length relationship with its associate entities.

Research Analyst or his/her relative(s) may have financial interest in the subject company. Elara Securities (India) Private Limited does not have any financial interest in the subject company, whereas its associate entities may have financial interest. Research Analyst or his/her relative does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relative or Elara Securities (India) Private Limited or its associate entities does not have any other material conflict of interest at the time of publication of the Research Report.

Research Analyst or his/her relative(s) has not served as an officer, director or employee of the subject company.

Research analyst or Elara Securities (India) Private Limited have not received any compensation from the subject company in the past twelve months. Associate entities of Elara Securities (India) Private Limited may have received compensation from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company or third party in connection with the Research Report in the past twelve months.

#### Disclaimer & Standard warning

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

## Elara Securities (India) Private Limited



#### Disclaimer for non U.S. Investors

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

#### Disclosures for U.S. Investors

The research analyst did not receive compensation from Dhanuka Agritech Limited.

Elara Capital Inc.'s affiliate did not manage an offering for Dhanuka Agritech Limited.

Elara Capital Inc.'s affiliate did not receive compensation from Dhanuka Agritech Limited in the last 12 months.

Elara Capital Inc.'s affiliate does not expect to receive compensation from Dhanuka Agritech Limited in the next 3 months.

### Disclaimer for U.S. Investors

This material is based upon information that we consider to be reliable, but Elara Capital Inc. does not warrant its completeness, accuracy or adequacy and it should not be relied upon as such.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities, financial instruments or strategies mentioned herein may not be suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only correct as of the stated date of their issue. Prices, values or income from any securities or investments mentioned in this report may fall against the interests of the investor and the investor may get back less than the amount invested. Where an investment is described as being likely to yield income, please note that the amount of income that the investor will receive from such an investment may fluctuate. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. The information contained in this report does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation of particular securities, financial instruments or strategies to you. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.

Certain statements in this report, including any financial projections, may constitute "forward-looking statements." These "forward-looking statements" are not guarantees of future performance and are based on numerous current assumptions that are subject to significant uncertainties and contingencies. Actual future performance could differ materially from these "forward-looking statements" and financial information.



# Elara Securities (India) Private Limited

India	Europe	USA	Asia / Pacific
Elara Securities (India) Pvt. Ltd.	Elara Capital Plc.	Elara Securities Inc.	Elara Capital (Asia) Pte.Ltd.
One International Center, Tower 3, 21st Floor,	6th Floor, The Grove,	230 Park Avenue, Suite 2415, New	One Marina Boulevard,
Senapati Bapat Marg, Elphinstone Road (West)	248A Marylebone Road,	York, NY 10169, USA	Level 20,
Mumbai – 400 013, India	London, NW1 6JZ, United Kingdom	Tel: +1 212 430 5870	Singapore 018989
Tel: +91 22 6164 8500	Tel: +44 20 7486 9733	Fax: +1 212 208 2501	Tel: +65 6978 4047

Tel: +91 22 6164 8500		Tel : +44 20 7486 9733	Fax: +1 212 208 2501 T	el : +65 6978 4047
Harendra Kumar	Managing D	irector	harendra.kumar@elaracapital.com	+91 22 6164 8571
Sales	Ivial laying D	iiectoi	патенита.китпате етагасаркат.сотт	171 22 010+ 0371
Ashok Agarwal	India		ashok.agarwal@elaracapital.com	+91 22 6164 8558
Hitesh Danak	India		hitesh.danak@elaracapital.com	+91 22 6164 8543
Karan Rathod	India		karan.rathod@elaracapital.com	+91 22 6164 8570
Lekha Nahar	India		lekha.nahar@elaracapital.com	+91 22 6164 8512
Prashin Lalvani	India		prashin.lalvani@elaracapital.com	+91 22 6164 8544
	India			+91 22 6164 8544
Shraddha Shrikhande			shraddha.shrikhande@elaracapital.com	
Sudhanshu Rajpal	India		sudhanshu.rajpal@elaracapital.com	+91 22 6164 8508
Joshua Saldanha	Asia	6 5 F	joshua.saldanha@elaracapital.com	+91 22 6164 8541
Anita Nazareth			anita.nazareth@elaracapital.com	+91 22 6164 8520
Tina D'souza	Corporate A		tina.dsouza@elaracapital.com	+91 22 6164 8595
Quantitative, Alternatives, S				.01 33 / 1/ 4 0F31
Sunil Jain		& Alternates	sunil.jain@elaracapital.com	+91 22 6164 8531
Nandish Patel	Quantitative		nandish.patel@elaracapital.com	+91 22 6164 8564
Biren Mehta	Head - Sales	Trading	biren.mehta@elaracapital.com	+91 22 6164 8500
Kalpesh Parekh	India		kalpesh.parekh@ElaraCapital.com	+91 22 6164 8555
Manoj Murarka	India		manoj.murarka@elaracapital.com	+91 22 6164 8551
Anil Pawar	India		anil.pawar@elaracapital.com	+91 22 6164 8552
Nilesh Chheda	India		nilesh.chheda@elaracapital.com	+91 22 6164 8554
Nupur Barve	India		nupur.barve@elaracapital.com	+91 22 6164 8532
Research				
Dr Bino Pathiparampil	Head of Research	ch Healthcare, Pharmaceuticals, Strategy	bino.pathiparampil@elaracapital.com	+91 22 6164 8689
Amit Purohit	Analyst	Building Materials, FMCG, Paints	amit.purohit@elaracapital.com	+91 22 6164 8594
Ankita Shah	Analyst	Infrastructure, Ports & Logistics, Industrials	ankita.shah@elaracapital.com	+91 22 6164 8516
Biju Samuel	Analyst	Quantitative & Alternate Strategy	biju.samuel@elaracapital.com	+91 22 6164 8505
		Aviation, Chemicals, Oil & Gas		+91 22 6164 8505
Gagan Dixit	Analyst Economist	Aviation, Chemicais, Oil & das	gagan.dixit@elaracapital.com garima.kapoor@elaracapital.com	+91 22 6164 8527
Garima Kapoor		6it-l 6 t- 6		
Harshit Kapadia	Analyst	Capital Goods, Consumer Electronics	harshit.kapadia@elaracapital.com	+91 22 6164 8542
Jay Kale, CFA	Analyst	Auto & Auto Ancillaries	jay.kale@elaracapital.com	+91 22 6164 8507
Karan Taurani	Analyst	Media & Entertainment, Alcobev, QSR, Internet		+91 22 6164 8513
Prakhar Agarwal	Analyst	Banking & Financials	prakhar.agarwal@elaracapital.com	+91 22 6164 8502
Prashant Biyani	Analyst	Agrochemicals, Fertilisers, Hotels, Sugar	prashant.biyani@elaracapital.com	+91 22 6164 8581
Prerna Jhunjhunwala	Analyst	Textiles, Retail	prerna.jhunjhunwala@elaracapital.co	
Ravi Sodah	Analyst	Cement, Metals & Mining	ravi.sodah@elaracapital.com	+91 22 6164 8517
Rupesh Sankhe	Analyst	Utilities, Renewables, Capital Goods, Real Estate		+91 22 6164 8518
Shweta Daptardar	Analyst	Diversified Financials, Non Lending Financials	shweta.daptardar@elaracapital.com	+91 22 6164 8559
Saurabh Mitra	Sr. Associate	Cement, Metals & Mining	saurabh.mitra@elaracapital.com	+91 22 6164 8546
Aditya Jaiswal	Associate	Strategy	aditya.jaiswal@elaracapital.com	+91 22 4204 8683
Amogh Deshpande	Associate	Aviation, Chemicals, Oil & Gas	amogh.deshpande@elaracapital.com	
Bhavi Shah	Associate	Cement, Metals & Mining	bhavi.shah@elaracapital.com	+91 22 6164 8521
Devarshi Raj	Associate	Diversified Financials, Non Lending Financials	devarshi.raj@elaracapital.com	+91 22 6164 8500
Gnyan Thaker	Associate	Textiles, Retail	gnyan.thaker@elaracapital.com	+91 22 6164 8500
Jinesh Kothari	Associate	Infrastructure, Ports & Logistics	jinesh.kothari@elaracapital.com	+91 22 6164 8500
Kartik Solanki	Associate	Banking & Financials	kartik.solanki@elaracapital.com	+91 22 4204 8604
Kashish Thakur	Associate	Healthcare, Pharmaceuticals	kashish.thakur@elaracapital.com	+91 22 6164 8569
Keval Shah	Associate	Strategy	keval.shah@elaracapital.com	+91 22 4204 8669
Mihir Vora	Associate	Auto & Auto Ancillaries	mihir.vora@elaracapital.com	+91 22 6164 8500
Mudit Kabra	Associate	Capital Goods, Consumer Electronics	mudit.kabra@elaracapital.com	+91 22 4204 8611
Nemish Sundar	Associate	Capital Goods, Consumer Electronics	nemish.sundar@elaracapital.com	+91 22 4204 8683
Nishant Chowhan, CFA	Associate	Auto & Auto Ancillaries	nishant.chowhan@elaracapital.com	+91 22 4204 8667
Palak Shah	Associate	Banking & Financials	palak.shah@elaracapital.com	+91 22 4204 8682
Ragini Pande	Associate	Utilities, Renewables	ragini.pande@elaracapital.com	+91 22 6164 8500
Rohit Harlikar	Associate	Building Materials, FMCG, Paints	rohit.harlikar@elaracapital.com	+91 22 6164 8562
Rounak Ray	Associate	Media & Entertainment, Alcobev, QSR, Internet	rounak.ray@elaracapital.com	+91 22 4204 8684
Runit Kapoor	Associate	Healthcare, Pharmaceuticals	runit.kapoor@elaracapital.com	+91 22 6164 8500
Shweta Roy	Associate	Economics	shweta.roy@elaracapital.com	+91 22 6164 8500
Subhankar Sanyal	Associate	Economics	subhankar.sanyal@elaracapital.com	+91 22 4204 8688
Tanvi Tambat	Associate	Real Estate	tanvi.tambat@elaracapital.com	+91 22 6164 8537
Ujwal Wadighare	Associate	Agrochemicals, Fertilisers, Hotels, Sugar	ujwal.wadighare@elaracapital.com	+91 22 4204 8684
Vidhi Puj	Associate	Building Materials, FMCG, Paints	vidhi.puj@elaracapital.com	+91 22 4204 8692
Vinayak Patil	Database	g, . <del></del> ,	vinayak.patil@elaracapital.com	+91 22 6164 8510
Priyanka Sheth	Editor		priyanka.sheth@elaracapital.com	+91 22 6164 8568
Prakriti Singh	Editor		prakriti.singh@elaracapital.com	+91 22 6164 8500
Gurunath Parab	Production		gurunath.parab@elaracapital.com	+91 22 6164 8515
Jinesh Bhansali	Production		jinesh.bhansali@elaracapital.com	+91 22 6164 8537
			,	0.0.0337

Access our reports on Bloomberg: Type RESP ESEC <GO>

Also available on Thomson & Reuters

#### Elara Securities (India) Private Limited

Elara Securities (India) Private Limited

Registered Office Address: One International Center, Tower 3, 21st Floor, Senapati Bapat Marg,
Elphinstone Road (West) Mumbai – 400 013, India Tel: +91 22 6164 8500

CIN: U74992MH2007PTC172297 | SEBI Research Analyst Registration No.: INH000000933

Member of BSE Limited and National Stock Exchange of India Limited | SEBI REGN. NO.: INZ 000 238236

Member of Central Depository Services (India) Limited | SEBI REGN. NO.: IN-DP-370-2018

Investor Grievance Email ID: investor.grievances@elaracapital.com - Tel. +91 22 6164 8509

Compliance Officer: Mr. Anand Rao - Email ID: anand.rao@elaracapital.com - Tel. +91 22 6164 8509